X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6179) 6179
Book Review (1418) 1418
Publication (844) 844
Book Chapter (48) 48
Conference Proceeding (18) 18
Dissertation (7) 7
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4363) 4363
humans (4005) 4005
braf (3293) 3293
oncology (2690) 2690
melanoma (2633) 2633
mutation (2174) 2174
cancer (1941) 1941
proto-oncogene proteins b-raf - genetics (1690) 1690
female (1492) 1492
male (1398) 1398
middle aged (1121) 1121
metastatic melanoma (1066) 1066
vemurafenib (1045) 1045
melanoma - drug therapy (957) 957
melanoma - genetics (946) 946
aged (939) 939
animals (938) 938
tumors (930) 930
adult (876) 876
genetic aspects (873) 873
metastasis (849) 849
cell line, tumor (837) 837
melanoma - pathology (830) 830
mutations (768) 768
cell biology (767) 767
braf mutation (725) 725
care and treatment (724) 724
proto-oncogene proteins b-raf - antagonists & inhibitors (707) 707
gene mutations (696) 696
research (696) 696
braf mutations (674) 674
antineoplastic agents - therapeutic use (656) 656
pathology (647) 647
analysis (644) 644
survival (633) 633
neoplasms (610) 610
kinases (607) 607
article (604) 604
prognosis (590) 590
colorectal cancer (587) 587
dermatology (573) 573
proto-oncogene proteins b-raf - metabolism (567) 567
resistance (564) 564
expression (543) 543
open-label (536) 536
chemotherapy (517) 517
mice (515) 515
immunotherapy (505) 505
health aspects (489) 489
activation (485) 485
protein kinase inhibitors - pharmacology (485) 485
kras (484) 484
skin neoplasms - pathology (482) 482
acquired-resistance (474) 474
aged, 80 and over (473) 473
targeted therapy (454) 454
therapy (451) 451
b-raf (450) 450
signal transduction (447) 447
dabrafenib (446) 446
skin neoplasms - genetics (438) 438
malignant-melanoma (428) 428
antineoplastic agents - pharmacology (425) 425
protein kinase inhibitors - therapeutic use (419) 419
melanoma - metabolism (418) 418
skin neoplasms - drug therapy (417) 417
biochemistry & molecular biology (416) 416
inhibition (410) 410
apoptosis (409) 409
medicine & public health (409) 409
pathway (408) 408
immunohistochemistry (405) 405
proteins (398) 398
mek inhibition (394) 394
carcinoma (378) 378
thyroid cancer (375) 375
treatment outcome (375) 375
colorectal neoplasms - genetics (372) 372
patients (371) 371
molecular targeted therapy (365) 365
gene expression (356) 356
development and progression (350) 350
pharmacology & pharmacy (346) 346
improved survival (340) 340
braf inhibitor (339) 339
digestive system diseases (336) 336
cells (328) 328
drug therapy (328) 328
medicine, research & experimental (327) 327
metastases (320) 320
braf inhibitors (309) 309
thyroid neoplasms - genetics (309) 309
mutation - genetics (307) 307
braf v600e mutation (300) 300
ipilimumab (297) 297
mek (297) 297
diagnosis (296) 296
dna mutational analysis (293) 293
gene (290) 290
biomarkers, tumor - genetics (287) 287
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6069) 6069
German (61) 61
French (54) 54
Polish (11) 11
Korean (6) 6
Spanish (6) 6
Chinese (3) 3
Czech (3) 3
Russian (3) 3
Japanese (2) 2
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Chromatography B, ISSN 1570-0232, 10/2016, Volume 1033-1034, pp. 390 - 398
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 376, Issue 1, pp. 43 - 52
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
Nature, ISSN 0028-0836, 12/2011, Volume 480, Issue 7377, pp. 387 - 390
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2018, Volume 142, Issue 10, pp. 2139 - 2152
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are currently in clinical trials... 
melanoma | BRAF | drug resistance | drug tolerance | CDK4 | DABRAFENIB | SAFETY | RAS | IMPROVED SURVIVAL | PHASE-3 | BRAF(V600E) | METASTATIC MELANOMA | ONCOLOGY | PLUS TRAMETINIB | SENESCENCE | VEMURAFENIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Humans | Melanoma - enzymology | Drug Resistance, Neoplasm | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Female | Indoles - pharmacology | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | MAP Kinase Kinase Kinases - antagonists & inhibitors | Pyridines - administration & dosage | Mice, SCID | Sulfonamides - pharmacology | Piperazines - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Melanoma - drug therapy | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Sulfonamides - administration & dosage | Medical research | Senescence | Effectiveness | Tumor cells | Xenotransplantation | MEK inhibitors | Melanoma | Clinical trials | Immunological tolerance | Cyclin-dependent kinase 4 | Signaling | Inhibitors | Robustness (mathematics) | Cell death | Cell lines | Xenografts | In vivo methods and tests | Inhibition | Tumors | Index Medicus
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 07/2015, Volume 28, Issue 4, pp. 417 - 430
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 2018, Volume 293, Issue 37, pp. 14276 - 14284
The dimerization-driven paradoxical activation of RAF proto-oncogene Ser/Thr kinase (RAF) is the predominant cause of drug resistance and toxicity in cancer... 
14-3-3 | WILD-TYPE | ACTIVATED PROTEIN-KINASE | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | RAF inhibitor | BRAF | HETERODIMERIZATION | AMP-activated protein kinase | RAF/MEK/ERK PATHWAY | cancer therapy | paradoxical activation | cell signaling | cancer | cancer biology | drug resistance | B-RAF | OLIGOMERIZATION | RAF kinase | DEPENDENT MECHANISM | Index Medicus | Signal Transduction
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 2, pp. 406 - 410
Abstract BRAF-mutant melanoma can be successfully treated by BRAF kinase inhibitors (BRAFi) and MEK kinase inhibitors (MEKi). However, the administration of... 
Hematology, Oncology and Palliative Medicine | MAPK pathway | Melanoma | BRAF inhibitor | MEK inhibitor | Sequenced administration | Downstream inhibition | Upstream inhibition | APOPTOSIS | TRAMETINIB | IMPROVED SURVIVAL | OPEN-LABEL | PHASE-2 | CANCER | METASTATIC MELANOMA | ONCOLOGY | RESISTANCE | MUTATIONS | VEMURAFENIB | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Indoles - administration & dosage | Feasibility Studies | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Time Factors | Melanoma - genetics | Aged, 80 and over | Female | Retrospective Studies | Proto-Oncogene Proteins B-raf - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Mitogen-Activated Protein Kinases - metabolism | Gene mutations | Protein kinases | Mitogens | Analysis | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2010, Volume 464, Issue 7287, pp. 427 - 430
Tumours with mutant BRAF are dependent on the RAF–MEK–ERK signalling pathway for their growth. We found that ATP-competitive RAF inhibitors inhibit ERK... 
SELECTIVE INHIBITOR | ACTIVATION | MELANOMA | MECHANISM | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | HETERODIMERIZATION | KINASE INHIBITOR | B-RAF | CRAF | ONCOGENIC BRAF | Neoplasms - metabolism | ras Proteins - genetics | Phosphorylation | raf Kinases - antagonists & inhibitors | Humans | Protein Multimerization | Transcriptional Activation - drug effects | ras Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Mitogen-Activated Protein Kinase Kinases - metabolism | Neoplasms - genetics | Adenosine Triphosphate - metabolism | Indoles - pharmacology | raf Kinases - genetics | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Cell Line | raf Kinases - chemistry | Catalytic Domain | Neoplasms - enzymology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | MAP Kinase Signaling System - drug effects | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Protein Binding | Mice | Protein Kinase Inhibitors - pharmacology | Protein Kinase Inhibitors - metabolism | Care and treatment | Enzyme inhibitors | Gene mutations | Cellular signal transduction | Genetic aspects | Research | Health aspects | Cancer | Proteins | Competition | Drugs | Mutation | Kinases | Tumors | Index Medicus
Journal Article
Journal Article
Journal Article